Teladoc Health (TDOC) EBITDA (2014 - 2026)

Teladoc Health (TDOC) has 13 years of EBITDA data on file, last reported at -$59.3 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 49.33% year-over-year to -$59.3 million; the trailing twelve-month figure through Mar 2026 stood at -$191.9 million (up 81.61% YoY), and the FY2025 full-year result was -$249.6 million, up 75.3% from the prior year.
• EBITDA eased to -$59.3 million in Q1 2026, from -$33.2 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $54.5 million in Q1 2022 to a low of -$3.8 billion in Q4 2022.
• A 5-year average of -$491.7 million and a median of -$59.3 million in 2026 frame the typical range for EBITDA.
• Peak annual rise in EBITDA reached 164.36% in 2022, while the deepest fall reached 9109.86% in 2022.
• Tracing TDOC's EBITDA over 5 years: stood at -$3.8 billion in 2022, then surged by 99.15% to -$32.3 million in 2023, then tumbled by 40.1% to -$45.2 million in 2024, then climbed by 26.61% to -$33.2 million in 2025, then tumbled by 78.65% to -$59.3 million in 2026.
• Business Quant data shows TDOC's EBITDA at -$59.3 million in Q1 2026, -$33.2 million in Q4 2025, and -$49.3 million in Q3 2025.